Policy Review reveals obstacles to access less costly, life-saving drugs for patients in the U.S.

December 2, 2020

Alt Text

Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin and Herceptin. In a Policy Review in The Lancet Oncology, Y. Tony Yang, a professor at the George Washington University School of Nursing and Milken Institute School of Public Health, along with researchers at the University of South Carolina, the City of Hope Comprehensive Cancer Center in Duarte, California, the Virginia Mason Cancer Institute and Saint Louis University School of Medicine, identify factors preventing the effective launch of oncology biosimilars in the United States, including the struggle to garner market share and fighting patent litigation lawsuits across the country. They also report inadequate rollouts for the first wave of oncology biosimilars for AMGEN’s supportive care cancer drugs Neupogen, Epogen and Neulasta.

Read more about Dr. Yang's report in The Lancet Oncology